Clinical progress of paroxysmal nocturnal hemoglobinuria / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1627-1630, 2013.
Artigo
em Chinês
| WPRIM
| ID: wpr-264963
ABSTRACT
Through the applications of high-sensitivity flow cytometry of FLAER and the treatment of eculizumab, it is necessary to understand of paroxysmal nocturnal hemoglobinuria (PNH) from a new point of view. The results of studies demonstrate that treatment with eculizumab alters the natural history of PNH by virtually eradicating thromboembolic complications, inhibiting of intravascular hemolysis and reducing or eliminating transfusion requirements. Eculizumab treatment may also reduce disease-related mortality. This review focuses on the studies to define the relationship between PNH and bone marrow failure syndromes and to characterize the long-term outcome of patients with PNH treated with eculizumab. New therapeutic strategies aimed at controlling extravascular and intravascular hemolysis are discussed.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Prognóstico
/
Terapêutica
/
Complemento C5
/
Usos Terapêuticos
/
Diagnóstico
/
Alergia e Imunologia
/
Anticorpos Monoclonais Humanizados
/
Hemoglobinúria Paroxística
Tipo de estudo:
Estudo diagnóstico
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS